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ABSTRACT 
Objectives: Measures of patient-reported health are increasingly used in clinical and 
health system decisions, and the EQ-5D is one of the most widely used questionnaires. It 
is recommended by NICE and is widely used in clinical trials, as well as in population 
health surveys and the NHS PROMs programme. A new version, the EQ-5D-5L, is now 
available. The objective of this study is to establish how important different sorts of 
health problems are to overall quality of life, and to produce the set of scores (‘value 
set’) required to use EQ-5D-5L data in decision-making and priority setting in the English 
NHS. 
Design: The study design followed an international research protocol. Each participant 
valued 10 health states using a time trade-off approach and completed seven discrete 
choice tasks. The data are used to model values for all 3,125 states described by the EQ-
5D-5L. 
Setting: England general population. 
Participants: Data were collected in face-to-face interviews with 996 adult members of 
the general public, selected at random from residential postcodes. The sample is broadly 
representative of the general population. 
Results: The data obtained from participants had good face validity. Problems with 
pain/discomfort and anxiety/depression were the most important factor in overall quality 
of life. Values ranged from -0.281 (for extreme problems on all dimensions) to 0.951.  
Conclusions: The value set reported here will have important implications for public 
decisions made using EQ-5D-5L data. There are considerably fewer states judged to be 
‘worse than dead’ compared to the current EQ-5D value set (4.93%, compared with over 
one-third) and the minimum value is higher (-0.281 compared to -0.594). The results 
imply that QALY gains for interventions seeking to improve very poor health will be 
smaller using the EQ-5D-5L tariff, and may previously have been overestimated.  
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1. INTRODUCTION 
Clinical practice requires decisions to be made under uncertainty, whereby any decision 
may have a range of different outcomes. To make the ‘best’ decision, potential outcomes 
need ordering and valuing. Such decisions are made both at the individual level, such as 
choosing the optimal treatment for a patient, and at the national level, such as choosing 
how to allocate resources between treatments for different patient groups and across 
different health conditions.  
Clinical decisions often affect patients’ health-related quality of life (HRQL). Evidence on 
patients’ HQRL can be obtained using ‘patient-reported outcome’ (PRO) measures. These 
may be condition-specific or generic. Condition-specific PROs focus on specific health 
problems and aim to provide detailed information about the impacts of the condition, 
disregarding problems which are atypical for the condition. Generic PROs aim to cover a 
more general spectrum of health problems, and are designed to be applicable for any 
health condition. They can capture co-morbidities, and allow comparisons with 
‘population norms’. Evidence obtained from generic measures can be used to compare 
both the impact of health problems and the benefits offered by treatments across 
different patient populations and disease areas. This makes these data particularly useful 
for the decisions made by general practitioners, commissioners, regulators, the National 
Institute for Health and Care Excellence (NICE) and the NHS.  
The EQ-5D is the most widely used generic PRO questionnaire internationally (Kind et al., 
2005). It is the instrument recommended by NICE for evidence submitted to its 
technology appraisal process (NICE, 2013). It has also proved useful in population health 
surveys and in the English NHS PROMs programme (Devlin and Appleby 2010). The EQ-
5D asks patients to indicate whether they have no, some or extreme problems on each 
of five dimensions of health: mobility; self-care; usual activities; pain/discomfort; 
anxiety/depression. 
The EQ-5D is a valid and reliable measure in many disease areas (Janssen et al., 2011; 
Wailoo et al., 2010; Pickard et al., 2007). However, there have been concerns that three 
response options for each dimension may not adequately capture milder health problems 
experienced by patients, and smaller changes between different health states. A new 
version of the instrument, the EQ-5D-5L, was developed to improve sensitivity and to 
standardise the language used across dimensions (Herdman et al., 2011). The EQ-5D-5L 
comprises the same five dimensions, but increases the available response options 
(‘levels’) from three to five (no; slight; moderate; severe; extreme problems/unable to) 
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– see Figure 1. The five dimensions and five levels of the EQ-5D-5L describe 3,125 (55) 
unique health states, compared to the 243 (35) described by the EQ-5D.  
 
Figure 1. The EQ-5D-5L descriptive system 
 
Note: The figure above is provided for illustrative purposes only. The full EQ-5D-5L questionnaire is available 
from the EuroQol Research Foundation.  
 
The EQ-5D-5L is rapidly being incorporated into routine data collection in clinical 
settings, clinical trials and population health surveys (such as the GP Patient Survey and 
the Health Survey for England). It is also used in local initiatives – for example, the 
Cambridgeshire Community Services NHS Trust collects EQ-5D-5L data to evaluate 
outcomes from rehabilitation services (Cambridgeshire Community Services NHS Trust, 
2013-2014). Its design accounts for the need for a direct link between the measurement 
and valuation of health, whereby every ‘health state’ – i.e. combination of health 
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problems – which patients might report on the EQ-5D-5L instrument can be summarised 
by a single value. In order to be used in the calculation of quality-adjusted life years 
(QALYs; a metric used in cost-utility analysis that combines survival and HRQL), these 
health state values needs to summarise how good or bad the health problems described 
are on a scale anchored at 1 (full health) and 0 (a state equivalent to dead). Health 
states considered to be worse than dead are given values less than 0. The values are 
based on the views of the general public who are asked to imagine living in various 
health states, and to respond to a series of structured questions designed to find out the 
importance to them of different aspects of health. This approach follows the 
requirements of NICE (2013) and similar organisations for the use of EQ-5D-5L data in 
decision making, and reflects a belief that it is the views of the general public – as 
taxpayers and potential users of health care – that should count, rather than simply 
those of patients (Gold et al., 1996).  
 
Value sets for the (three-level) EQ-5D are available for a range of countries (Szende et 
al., 2007). The current UK EQ-5D value set (Dolan, 1997) has values which range from 1 
for no problems on any dimension to -0.594 for the worst health state (level 3 problems 
on each dimension). A number of limitations have been noted with that value set. 
Among these are that approximately a third of health states described by the EQ-5D 
were assigned negative values, meaning those health states are valued as being ‘worse 
than dead’. The UK values are rather unique in this respect: all other countries have 
higher values. Additionally – although also common to other countries – any change in 
health away from full health to ‘some’ problems, on any aspect of health, results in a 
large fall in the overall value (of at least 0.12) on the 0 to 1 scale. These issues with the 
current EQ-5D value set may have important implications for decisions being made in 
the NHS. For example, NICE estimates of QALY gains from new treatments may be 
biased upwards.
 
(Devlin et al., 2011; Devlin et al., 2012). 
 
To date there have been no values specific to the (five-level) EQ-5D-5L available to 
summarise patients’ data. Research has established the relationship between patients’ 
self-reported health on the EQ-5D and on the EQ-5D-5L, enabling EQ-5D-5L data 
collected from patients to be summarised using the EQ-5D value set, via a ‘mapping 
algorithm’ (van Hout et al., 2012) This provides an interim means of scoring EQ-5D-5L 
data, but perpetuates the limitations of the EQ-5D value set (Devlin et al., 2011; Devlin 
et al., 2012; Tilling et al., 2010) 
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The aim of this study is to produce a ‘value set’ for the EQ-5D-5L that can be used to 
support decision making in the English NHS. This is one of the first value sets to be 
reported for the EQ-5D-5L internationally. The study is relevant to clinicians collecting 
PRO data from patients, and to those using PRO data in health care decisions. It 
demonstrates the relative importance placed on different types of health problems by 
people in England – and how that should be reflected in priority-setting. 
 
2. METHODS 
The research design and data collection followed a research protocol developed by the 
EuroQol Research Foundation, a not-for-profit international network of multidisciplinary 
researchers. The protocol was informed by an extensive programme of methodological 
research investigating methods for valuing EQ-5D-5L health states (Oppe et al., 2014). 
Our study was one of the first to use the protocol, and comparable studies are now 
underway worldwide.  
 
2.1 Methods of eliciting preferences 
The study used the EuroQol Valuation Technology (EQ-VT) software, developed 
specifically for EQ-5D-5L value set studies and administered using computer-assisted 
personal interviews. Two stated preference methods were used to elicit preferences: 
time trade-off (TTO) – an approach used in previous EQ-5D valuation studies (Oppe et 
al., 2014) and accepted by NICE as a ‘choice-based’ approach (NICE, 2013) and discrete 
choice experiments (DCE) – an approach that is increasingly used to assess preferences 
for health states because of the relative simplicity of the tasks (Ryan et al., 2008). The 
two methods generate different and complementary preference data. TTO elicits a value 
for each state with 1 and 0 defined as anchor points, whereas DCE generates binary data 
which allow for the derivation of a scale of non-anchored relative values.  
Each interview consisted of the following tasks (in order): self-reported health using EQ-
5D-5L, self-reported health on a 0-100 visual analogue scale (EQ-VAS); basic 
background questions; a practice TTO task (involving the valuation of a simple health 
state describing being confined to a wheelchair); 10 TTO tasks; structured feedback 
questions regarding the TTO tasks; seven DCE tasks; structured DCE feedback 
questions; an (optional) open-ended comment box; and further background questions.  
In the TTO tasks, a composite approach was used which involved starting with the 
‘conventional’ TTO (Brazier et al., 2007) for all health states, and shifting to a ‘lead time’ 
TTO when participants indicated that they considered the health state to be worse than 
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dead (Devlin et al., 2011; Devlin et al., 2012; Robinson and Spencer, 2006). The 
composite TTO approach is illustrated in Figures 2a and 2b. Evidence supporting this 
approach is reported by Janssen et al. (2013). 
Figure 2a illustrates the TTO task for health states better than dead (i.e. those with a 
value between 0 and 1). The participant is asked to imagine living for 10 years from 
today in a given EQ-5D-5L state, followed by death (‘Life B’). The participant’s value for 
that health state is then derived by identifying, using a systematic iterative process, the 
number of years in full health between 0 and 10 (‘Life A’) they consider equivalent to 
that.  
The more severe the health state described in Life B, the more years of full health the 
participant is assumed to be willing to give up in Life A to avoid Life B. For very poor 
health states, all of the time in Life A may be traded off, indicating that the value for the 
state is less than or equal to 0. Where this occurs, additional time in full health (‘lead 
time’) is added to both Life A and Life B – see Figure 2b. This allows participants to trade 
off more time, reflecting how much worse than dead they consider the health state to be 
(within the boundaries of the scale imposed by the task) (Devlin et al., 2012). 
Figure 2a. TTO valuation of health states better than dead (i.e. values ≥ 0) 
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Figure 2b. TTO valuation of health states worse than dead (i.e. values ≤ 0) 
 
Source: Reproduced with the permission of the EuroQol Research Foundation.  
 
The variant of lead time TTO used in this study involved a 20 year time frame (10 years 
of lead time followed by 10 years in the health state under evaluation), yielding a 
minimum value of -1. No additional trade-off questions were asked of those who 
‘exhausted’ their lead time (Devlin et al., 2012). 
The iterative procedure used to seek the point of indifference was based on an 
adaptation of that used in the UK EQ-5D value set study (Dolan 1997). Further details 
about EQ-VT and the iterative process used in the TTO tasks are provided by Oppe et al 
(2014).  
Each TTO task ends when the participant indicates that they consider Life A and Life B to 
be ‘about the same’. At this point of indifference, the implied value for health states 
better than dead is calculated by dividing the total number of years in Life A (t) by 10 
(the total number of years in Life B). This can be expressed as V=t/10, where V is health 
state value. For example, at the point of indifference shown in Figure 2a, the health 
state value would be 5/10=0.5. The implied value for health states worse than dead is 
calculated by subtracting 10 (the number of years of lead time) from the total number of 
years in Life A, then dividing by 10 (the total number of years in Life B, minus the 
number of years of lead time). This can be expressed as V=(t-10)/10. The point of 
indifference shown in Figure 2b would suggest a value of (5-10)/10=-0.5. The maximum 
value is 1, achieved when the participant considers 10 years in the health state to be as 
good as 10 years in full health. A value of 0 is given when the respondent considers the 
health state to be no better and no worse than dead. The minimum score of -1 (where 
all of the lead time is exhausted) is given when the participant considers the prospect of 
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living for 10 years in full health followed by 10 years in the health state to be worse than 
or equivalent to a life lasting 0 years (i.e. dying now).  
In each DCE task (Figure 3), participants were presented with a pair of health states 
(labelled A and B), with no reference to the duration of the states, and asked to indicate 
which they considered to be ‘better’ by clicking the appropriate button. No indifference 
option was included. 
Figure 3. Discrete choice experiment task  
 
Source: Reproduced with the permission of the EuroQol Research Foundation.  
 
2.2 Study design 
Overall, 86 health states were selected for valuation via TTO, and 196 pairs of health 
states for valuation via DCE. Participants were randomly assigned to one of 10 blocks of 
10 TTO tasks and to one of 28 blocks of seven DCE tasks. The order in which the states 
appeared within each type of task was also randomised. None of the pairs in the DCE 
design included a health state that logically dominated the other (i.e. at least as good on 
all five dimensions). Each block of TTO tasks contained a combination of mild, moderate 
and severe health states. All blocks included the worst health state in the EQ-5D-5L 
descriptive system (described as 55555, i.e. level 5 for all dimensions), and one of the 
least severe health states (with no problems on four dimensions and slight problems on 
one dimension, e.g. 21111).  
 
2.3 Data collection 
Sample recruitment and interviewing was carried out by the market research company 
Ipsos MORI. A sample of 2,020 addresses from 66 primary sampling units across 
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England was randomly selected based on postcode sectors using the Post Office small 
user Postcode Address File. This includes all private residential accommodation in 
England (communal establishments, such as prisons and care homes, were excluded). 
Thirty-seven addresses were selected systematically from an ordered list of all addresses 
within each sampling unit, ensuring that addresses were spread evenly across it. 
Interviewers sent an advance letter and information sheet to each selected address, 
together with an unconditional incentive of six first-class stamps. In each selected 
dwelling unit, all individuals aged 18 years and over were listed in alphabetical order by 
first name and one was selected randomly using a selection grid with no substitutes 
permitted. 
If the selected individual gave their informed consent to take part, they were interviewed 
in their own home. The participant was in control of the computer (laptop) throughout 
the tasks, with the interviewer guiding them through each step, following a script. The 
one-to-one setting allowed interviewers to provide detailed instruction and feedback 
where appropriate (Shah et al., 2013).  
Forty-eight interviewers were used, all of whom attended a full day briefing in which 
they were given intensive training on the methodology and study procedures by the 
research team. Interim data were monitored at the interviewer level, at least weekly. If 
an interviewer was found to be generating unusual or poor quality data (defined using 
criteria based on expected data characteristics, given previous research), they were 
given additional training. No data were removed at this stage. The study was given 
approval by the research ethics committee of the University of Sheffield’s School of 
Health and Related Research. 
 
2.4 Piloting 
The main study was preceded by a small pilot study (n=49), undertaken in August 2012. 
The pilot sample was recruited using quotas on age, gender and working status rather 
than using the systematic approach described above. The aims of the pilot were: to test 
for technical issues with EQ-VT; to test Ipsos MORI’s procedures and methods of 
encouraging participation; to seek interviewers’ feedback on the preliminary script and 
other materials; to seek participants’ feedback on the interview; to examine basic 
properties of the data generated; and to identify ways to improve the interviewer 
training process. 
The pilot was completed successfully, with no issues with EQ-VT reported by participants 
or interviewers. Several improvements were made as a result of the feedback received 
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during piloting. These included refinement of the interviewer script and improvements to 
the interviewer training process.  
 
2.5 Methods of analysis  
For both TTO and DCE, a range of descriptive analyses were conducted to assess data 
characteristics. For TTO this included examining the overall distribution of values, and 
correlating average values for each health state with its level sum score (a proxy for 
severity; e.g. the worst health state 55555 has a score of 5+5+5+5+5=25). For DCE, 
the proportion of participants choosing health state A was assessed in comparison to the 
difference in level sum scores between A and B, with the implicit assumption that health 
states with lower level sum scores would be more likely to be chosen overall.  
To generate the modelling dataset, we tested a range of possible exclusion criteria, 
reflecting alternative judgements that might be made about the quality of the data. We 
wished to minimise exclusions but sought to omit data which were clearly implausible. 
The final rules for the TTO data were to exclude: (a) participants who gave all 10 health 
states the same value (all health states cannot plausibly be given the same value given 
the severity range in each block); and (b) participants who gave the worst state, 55555, 
a value that was no lower than the value they gave to the mildest health state in their 
block. Both suggest either misunderstanding or lack of engagement. No DCE data were 
excluded. 
Modelling explicitly addressed observed characteristics of the data (Feng et al., 2015). 
First, the minimum TTO value is bounded at -1 by design, so we allowed for the 
possibility of values lower than that using survival analysis approaches for treating 
censored data. Second, the maximum TTO value is 1, again by design, so although there 
is an error distribution around observed values, that distribution is necessarily 
asymmetric at 1, biasing the values for mild health states downwards. Thus, the values 
at 1 were also considered to be censored. Third, there were some participants who used 
0 as the minimum value for more than one health state (almost always including health 
state 55555). This suggests that these participants were averse to giving negative TTO 
values. Those values were considered to be censored at zero. Furthermore, some 
participants gave health state 55555 a value of 0 whilst giving multiple other health 
states a negative value. This in an example of a ‘logical inconsistency’, since all health 
states dominate 55555. Those values were censored at 0.     
Further, we observed that participants more often disagree about the value of health 
states that are further away from full health, i.e. the variance of TTO values increases for 
worse health states. From eyeballing the valuation data at the individual participant 
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level, it was apparent that different groups of participants differed in their use of the 
scale, resulting in substantially different slopes (i.e. the relationships between disutility 
and health state severity). This could fundamentally be driven by the heterogeneity of 
participants in their views about death. The effect of heterogeneity was explored using 
models that introduced a parameter for the scale of disutility in health, which may differ 
between participants. The scale of disutility in health was assumed to follow a 
multinomial distribution with probability density on a number of latent groups. Each of 
the latent groups has its mean and variance for the distribution of the scale. In our 
analysis, we assessed models with two, three and four latent groups, eventually judging 
that the three-group model best fitted the data. We also accounted for 
heteroskedasticity within each latent group in the model. This was achieved by 
estimating two parameters per group for modelling the relationship between the mean 
and the variance of health states. 
Models were estimated with different degrees of freedom. The most restrictive model 
gives different weights to the five dimensions and assumes equal distances between 
levels. The second most restrictive adds different values for the levels with a distinction 
between ‘extreme’ and ‘unable to’ (the former is the level 5 label used for the 
pain/discomfort and anxiety/depression dimensions; the latter is the level 5 label used 
for the mobility, self-care and usual activities dimensions). The least restrictive model 
has a parameter for each decrement or step away from ‘no problems’ (level 1) on each 
dimension. The least restrictive model was considered the best specification as it applied 
no assumptions about the parameters. In total, the model estimated 20 parameters (4 
levels x 5 dimensions). Within these specifications, a range of alternative models was 
tested to capture the possibility of interaction effects between dimensions and levels.  
20 parameter models that involved TTO data showed logical inconsistencies in some 
dimensions. In the model used to produce the EQ-5D-5L value set for England, we 
applied restrictions to the parameters. Specifically, the level 2 parameters were 
estimated first, and parameters for subsequent levels were estimated by adding 
quadratic terms (which can be non-negative only, thereby ensuring that moving to worse 
levels of problems always resulted in an increase in disutility).  
Models were estimated separately for the TTO and DCE data, and then using a hybrid 
modelling approach which optimised the likelihood of both data sets at the same time 
and resulted in a single combined-data value function (Ramos-Goñi et al., in press)  
The sociodemographic composition of the sample was checked for representativeness 
against the general population. Models were estimated on data specific to selected 
sociodemographic groups (e.g. male participants vs. female participants) to check for 
any systematic differences.  
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All analyses were conducted in R3.2.0 and Winbugs 14.  
The methods and analyses reported in this paper comply with the CREATE guidelines for 
reporting valuation studies of multi-attribute utility-based instruments (Xie et al., 2015). 
The modelling methods are described in greater detail in an accompanying paper by 
Feng et al. (2015). 
 
3. RESULTS 
3.1 Sample 
The interviews were conducted between November 2012 and May 2013. Of the 
individuals invited to take part in the study, 996 completed the valuation questionnaire, 
comprising TTO tasks, DCE tasks and basic background questions, in full (response rate 
≈ 40%). In accordance with the ethical approval for this study, participants who did not 
complete the valuation questionnaire in full were excluded from the analysis, hence 
there are no missing TTO and DCE responses in our data set. Full background data were 
collected for 985 of the 996 participants (98.9%). Table 1 shows that the sample 
includes a larger proportion of retired individuals and a smaller proportion of younger 
individuals than in the general population (Office for National Statistics, 2011). The 
sample also includes a relatively large proportion of individuals with health problems. 
Table 1. Background characteristics of the sample 
 All participants 
(n=996)ii 
After exclusions 
(n=912)ii 
General populationi 
 N (%) N (%) % 
Age 
  18-29 
  30-44 
  45-59 
  60-74 
  75+ 
 
113 (11.3) 
298 (29.9) 
250 (25.1) 
207 (20.8) 
128 (12.9) 
 
105 (11.5) 
270 (29.6) 
227 (24.9) 
191 (20.9) 
119 (13.0) 
 
20.7% 
26.3% 
24.7% 
18.5% 
9.9% 
Gender 
  Male 
  Female 
 
405 (40.7) 
591 (59.3) 
 
372 (40.8) 
540 (59.2) 
 
49.2% 
50.8% 
Economic activity 
  Employed or self-employed 
  Retired 
  Student 
  Looking after home or family 
  Long-term sick or disabled 
  Other / none of the above 
 
504 (51.2) 
278 (28.2) 
20 (2.0) 
83 (8.4) 
48 (4.9) 
52 (5.3) 
 
463 (50.8) 
256 (28.1) 
19 (2.1) 
73 (8.0) 
42 (4.6) 
47 (5.2) 
 
59.4% 
13.1% 
8.8% 
4.2% 
3.9% 
10.6% 
Marital status 
  Never Married 
  Married 
  Same-sex civil partnership 
  Separated iii  
  Divorced  
  Widowed iv 
 
238 (24.2) 
466 (47.3) 
2 (0.20 
37 (3.8) 
131 (13.3) 
107 (10.9) 
 
225 (23.4) 
434 (47.6) 
2 (0.2) 
32 (3.5) 
119 (13.0) 
99 (10.9) 
 
34.6% 
46.6% 
0.2% 
2.7% 
9.0% 
6.9% 
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 All participants 
(n=996)ii 
After exclusions 
(n=912)ii 
General populationi 
  Prefer not to say 4 (0.4) 1 (0.1) N/A 
Religion 
  Christian 
  Any other religion 
  No religion 
  Religion not stated 
 
636 (64.6) 
60 (6.0) 
281 (28.5) 
8 (0.8) 
 
575 (63.9) 
53 (5.8) 
266 (29.6) 
6 (0.7) 
 
59.4% 
8.7% 
24.7% 
7.2% 
Ethnicity 
  White 
  Any other ethnic group 
  Prefer not to say 
 
900 (91.4) 
82 (8.3) 
3 (0.3) 
 
832 (92.4) 
67 (7.4) 
1 (0.1) 
 
85.4% 
14.6% 
N/A 
Day-to-day limitations due to 
health problem or disability 
  Limited a lot 
  Limited a little 
  Not limited 
 
 
111 (11.3) 
158 (16.0) 
716 (72.7) 
 
 
95 (10.6) 
144 (16.00 
661 973.40 
 
 
5.6%v 
7.1%v 
87.3%v 
Education 
  Degree 
  No degree 
 
211 (21.4) 
774 (78.6) 
 
201 (22.3) 
699 (77.7) 
 
 
Main language spoken 
  English 
  Any other language 
 
920 (93.40 
65 (6.6) 
 
847 (94.1) 
53 (5.9) 
 
Responsibility for children 
  Yes 
  No 
 
350 (35.5) 
635 (64.5) 
 
314 (34.90 
586 (65.1) 
 
Experience of serious illness 
  In self   
  In family 
  In caring for others  
 
330 (33.1) 
692 (69.5) 
416 (41.8) 
 
297 (33.0) 
636 (70.7) 
385 (42.8) 
 
Self-rated health using EQ-5D-5L 
  11111 
  Any other health state 
 
474 (47.6) 
522 (52.4) 
 
437 948.6) 
475 (52.8) 
 
Self-rated health using EQ-VAS 
  <80 
  80-89 
  90-99 
  100 
 
334 (33.5) 
256 (25.7) 
337 (33.8) 
69 (6.9) 
 
298 (33.1) 
241 (26.8) 
306 (34.0) 
67 (7.4) 
 
 
i Based on results of the 2011 UK Census (Office for National Statistics, 2011), where available 
ii Data on economic activity, marital status, religion, ethnicity, day-to-day limitations, main language and 
responsibility for children unavailable for a minority of participants  
iii Comprises individuals who are separated but still legally married or in a same-sex civil partnership 
iv Includes individuals who are the surviving partner from a same-sex civil partnership  
v Census data reported here refers to individuals aged 16-64 only 
 
3.2 Descriptive analysis 
Figure 4 shows the distribution of observed TTO values. There is some evidence of 
clustering at key values on the scale (1, 0.5 and 0) and of digit preference (where most 
values provided are ‘round’ numbers). Health states were given a value of -1 (indicating 
that the respondents exhausted all of the lead time available to them) on 400 occasions 
(4.02% of all TTO observations). There are few observations between 0 and -0.5.  
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We observed evidence of interviewer effects, with different proportions of worse than 
dead values depending on which interviewer participants were interviewed by. 
 
As a simple test of the face validity of the data, the means and medians of the TTO 
values were plotted against the level sum scores of the health states. The results (not 
shown here) show the expected negative relationship, i.e. the worse the health state, 
the lower the average observed value. Similarly, the proportion of those choosing A or B 
in the DCE tasks was strongly correlated to the difference in level sum score between the 
health states, i.e. the greater the difference in severity between any two states, the 
more likely participants were to choose the health state with the lower level sum score.   
Figure 4. Distribution of observed TTO values 
 
3.3 Exclusion criteria 
Twenty-three participants (2.3%) gave all 10 health states the same value, and 61 
participants (6.1%) valued 55555 no lower than the value they gave to the mildest 
health state. Excluding these participants gave a core modelling dataset of 912 
participants (9,120 TTO observations). Post-exclusions, health states were given a value 
of -1 on 392 occasions (4.30% of all TTO observations). 
 
Of the remaining individuals, 150 participants with more than one health state valued at 
0 were treated as censored on the assumption that 0 was the lowest value they were 
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willing to use. Censoring was also applied to 27 participants with inconsistent negative 
data (where 55555 was given a value of 0 and more than one other health states were 
given negative values). 
 
3.4 Modelling results and the value set 
When addressing the weights given to the different dimensions, the TTO data suggest 
weights for mobility, self-care, usual activities, pain/discomfort and anxiety/depression 
of 0.052, 0.046, 0.053, 0.078 and 0.077, respectively. The DCE data suggest weights of 
0.338, 0.241, 0.205, 0.406 and 0.393, respectively. Both methods suggest that 
pain/discomfort and anxiety/depression should receive the greatest weight.  
 
Table 2 presents the EQ-5D-5L value set based on a hybrid model combining the TTO 
and DCE data. The minimum value is -0.281 (for the worst health state, 55555) with 
4.93% of the 3,125 health states described by the EQ-5D-5L being valued as worse than 
dead. The size of the coefficients in Table 2 reflects the relative weight placed on 
different sorts of health problems by our sample.  For example, at the worst level of 
problem (level 5) that can be experienced, pain/discomfort is considered to have the 
greatest overall impact on HRQL (0.341), followed by anxiety depression (0.301), 
mobility (0.275), self-care (0.217) and usual activities (0.190). At lower levels of 
problems, anxiety/depression has the largest effect on HRQL, followed by 
pain/discomfort, self-care, usual activities and mobility.  
  
 19 
 
Table 2. An EQ-5D-5L value set for England  
 
Central 
estimate  
Standard 
Deviation  Value for health state 23245 
Constant 1.000  1.000 
Mobility      
slight 0.051 0.004 0.051 
moderate 0.063 0.004   
severe 0.212 0.006   
unable 0.275 0.006   
Self-care      
slight 0.057 0.004   
moderate 0.076 0.004 0.076 
severe 0.181 0.005   
unable 0.217 0.005   
Usual activities      
slight 0.051 0.004 0.051 
moderate 0.067 0.004   
severe 0.174 0.005   
unable 0.190 0.005   
Pain/discomfort      
slight 0.060 0.004   
moderate 0.075 0.005   
severe 0.276 0.007 0.276 
extreme 0.341 0.008   
Anxiety/depression      
slight 0.079 0.004   
moderate 0.104 0.005   
severe 0.296 0.007   
extreme 0.301 0.007 0.301 
Probability (group 1) 0.397 0.019 
0.397 x 0.427 + 0.270 x 0.939 + 
0.333 x 1.635 
Probability (group 2) 0.270 0.018 =0.9675 
Probability (group 3) 0.333 0.018  
Slope (group 1) 0.427 0.031  
Slope (group 2) 0.939 0.067  
Slope (group 3) 1.635 0.017  
The value for health state 23245 
1-0.9675 x (0.051+ 
0.076+0.051+0.276+0.301) 
=0.270 
 
Table 2 provides a worked example of how to calculate the values for health state 
23245, where the relevant decrement for each level of problem on each dimension is 
subtracted from the constant. The coefficients from the three latent classes are reported 
by the three probabilities and three slopes. These six coefficients are used to calculate 
the weighted average of slope. The weighted average of slope is a fixed coefficient (i.e. 
0.9675) to be multiplied by the sum of the five decrements while calculating values for 
all health states.   
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3.5 EQ-5D and EQ-5D-5L value set comparisons 
Table 3 compares the EQ-5D-5L value set with the original EQ-5D value set (Dolan, 
1997) and the crosswalk value algorithm reported by van Hout et al. (2012). The EQ-5D-
5L value set has a higher value for the worst possible health state and substantially 
fewer worse than dead values. The decrement from the best (11111) to next best health 
state is smaller for the EQ-5D-5L value set, as might be expected given differences in 
number of levels and labelling between the instruments (e.g. 11211 describes ‘slight’ 
problems performing usual activities in the five-level instrument and ‘some’ problems in 
the three-level version). Pain/discomfort has the largest decrement, while self-care and 
usual activities have the smallest. Figure 5 shows that the EQ-5D-5L value set has a 
normal distribution, in contrast to the EQ-5D value set which was characterised by two 
peaks. (Parkin et al., 2014)  
 
Table 3: Comparison of the key characteristics of 5L values, crosswalk values 
and 3L values  
 EQ-5D-5L value set Crosswalk value set EQ-5D value set 
% health states 
worse than dead  
4.93%  
(154 out of 3,125) 
26.7%  
(833 out of 3,125) 
34.6%  
(84 out of 243) 
Preferences 
regarding 
dimensions 
(ordered from 
most to least 
important §)  
Pain/Discomfort Pain/Discomfort Pain/Discomfort 
Anxiety/Depression Mobility  Mobility  
Mobility Anxiety/Depression Anxiety/Depression 
Self-care  Self-care Self-care 
Usual Activities Usual Activities Usual Activities 
Value of 55555 
(33333) 
-0.281   -0.594 -0.594 
Value of 11112* 0.924 0.879 0.848 
Value of 11121* 0.942 0.837 0.796 
Value of 11211* 0.951 0.906 0.883 
Value of 12111* 0.945 0.846 0.815 
Value of 21111* 0.951 0.877 0.850 
Minimum value  -0.281   -0.594 -0.594 
Maximum value  1 1 1 
*Note that for each of the asterisked health states, the level of problems indicated on the five-level and three-
level versions of EQ-5D differ: for example, on the EQ-5D-5L, 11112 means no problems on any dimension 
except mild problems with anxiety/depression, whereas on the EQ-5D, 11112 means no problems on any 
dimensions except some problems with anxiety/depression. A priori, we would expect the values for these 
health states to be higher in the EQ-5D-5L value set than the EQ-5D value set, which is what we observe. 
§Importance is judged by the size of the coefficient for level 5 in each dimension.  
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Figure 5. Frequency of values in the EQ-5D (left) and EQ-5D-5L (right) value 
sets 
      
 
4. DISCUSSION 
We have reported a value set for the EQ-5D-5L, based on the preferences of a random 
sample of the English general public. Such value sets promote consistency and 
comparability in assessments of HRQL across different patient groups. The value set can 
be used to summarise EQ-5D-5L data collected from patients in a wide range of contexts 
and in the economic evaluation of health care interventions to support resource 
allocation decisions.  
The preferences of the English public suggest that pain/discomfort and 
anxiety/depression are the health problems that are most important; while problems 
with self-care (ability to wash or dress oneself) and usual activities (e.g. ability to do 
work, study, housework, family or leisure activities) are less important. This reflects 
what members of the public deem important and has implications for the assessment of 
treatments that affect different aspects of HRQL. 
This is one of the first studies internationally to report a value set for the EQ-5D-5L. A 
strength of the study is that the data have been generated using a standard protocol 
developed following an international programme of work (Oppe et al., 2014). Similar 
studies are now underway in numerous countries worldwide, which will facilitate direct 
comparisons of preferences between populations. See Augustovski et al. (in press), 
Ramos-Goñi et al. (in press), and Xie et al. (2016) for details of three studies that 
followed the same protocol. A further strength of our study is that it has addressed 
problems with previous value sets for EQ-5D, particularly with respect to the values for 
‘worse than dead’ health states (Devlin et al., 2011; Devlin et al., 2012; Tilling et al., 
2010), providing an improved basis for the use of HRQL evidence in decision making. 
Further, innovative methods developed during the course of our study have 
strengthened the approach to modelling value sets – in particular, by allowing different 
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types of data (TTO and DCE) to be modelled together to providing complementary 
evidence on preferences; and by taking into account the nature of preference data that 
are ‘bounded’ (censored); heterogeneity of respondents’ views in health utilities; and 
heteroskedasticity of the error terms.   
Although our TTO data have good face validity, a potential limitation of our study is that 
there is evidence of clustering at certain values and of selective scale use. This could be 
linked to the relative difficulty of the TTO task, and the use of an automated process to 
guide its administration. Interviewer effects on TTO responses may also be important 
given potential differences in levels of interviewer abilities and engagement.  
We therefore sought to exclude problematic data that could justifiably be considered not 
to reflect participants’ true preferences, whilst avoiding the exclusion of inconvenient 
data based on subjective researcher judgements. This involved the exclusion of some 
participants’ data and the censoring of some values at and below 0. The alternative 
approach of including all data would have meant that the assumption of a normal error 
distribution would need reconsidering. This in turn would have necessitated arbitrary 
assumptions, potentially with less transparency than the methods we report here. We 
deemed it invalid to include these data and to knowingly assume the wrong error 
distribution.  
We tested an extensive range of model specifications in our econometric analysis, and 
each could feasibly have been used to generate a value set. The choice of the model 
reported in this paper necessarily reflects a number of researcher judgements about 
which model is ‘best’. For example, while we could have generated a value set based on 
TTO data alone, the final value set reported here is derived from a hybrid of both TTO 
and DCE data, on the grounds that the two methods provide different and 
complementary information about the views of the sample.  
Our choice of the least restrictive model is based on two considerations. First, there are 
strong prior grounds for selecting it, as it allows the values associated with different 
levels of problems to vary across the dimensions. Second, the overall model statistics, 
i.e. log likelihood, suggest that it better captures the nature of the preferences of the 
English general public than more restrictive models (Feng et al., 2015). Model fit was not 
improved by including interaction parameters, and so there are no such interaction 
terms in the value set. This is in contrast to the current EQ-5D value set, which included 
the so-called ‘N3 term’ (a parameter capturing an additional reduction in value to any 
health state with a level 3 problem on any dimension) (Dolan, 1997).  
The EQ-5D-5L value set differs from the original EQ-5D value set (Dolan, 1997) and the 
interim crosswalk EQ-5D-5L tariff (van Hout et al., 2012) in important ways. First, the 
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value for the worst state is higher – as expected, given well-known issues with the 
procedure for valuing health states worse than dead in the original value set study, 
which yielded values as low as -39 that required rescaling to -1. As well as a higher 
minimum value, the value set reported here also has considerably fewer states worse 
than dead (4.93%, compared to around a third in the original UK value set). The 
characteristics of the value set we report are more in line with those found in other 
countries (Szende et al., 2010). This may imply that the QALY gains for interventions 
targeting those in very poor health were overestimated previously. 
The greater descriptive sensitivity of EQ-5D-5L allows patients to give more refined 
HRQL measurement data as they have more levels over which to describe their health. 
However, this increased ability to capture responses to treatment may be somewhat 
counteracted by the nature of the value set reported here, as members of the general 
public did not, on the whole, think that there was an important and significant difference 
between levels 4 and 5 on some dimensions. This highlights an interesting disjunction 
between the patient’s perspective, when self-reporting their health on the EQ-5D-5L, and 
the perspective of the general public in valuing these states. Whose values should count 
in decision making using these data is a normative question (Brazier, 2008). Use of the 
general public’s preferences is consistent with the stated requirements of NICE (2013) – 
but whether patients’ preferences should be used instead is a question that should be 
given further consideration.  
It would be possible to develop a range of value sets, based on the preferences of 
different population sub-groups and methodologies, for use in different contexts. 
Additional analyses (to be reported separately) show some differences between the 
health state preferences of different age groups, such that value sets estimated from 
age-specific data would differ in important ways. However, the use of a single value set, 
such as the one we report here, allows for consistent decision making across patient 
populations and sociodemographic groups – which is particularly important where 
resource allocation decisions are concerned.  
This study raises a range of unanswered questions and areas for further research. First, 
the value set we have reported is for the English population. However, some health care 
decisions relate to different jurisdictions. For example, NICE decisions cover both 
England and Wales. The current UK EQ-5D value set is used by both NICE and the 
Scottish Medicines Consortium. Are the preferences of the UK population (i.e. including 
Scotland, Wales and Northern Ireland) consistent with the values reported here? We 
have collected additional data in order to generate a UK value set, which will be reported 
separately. Similarly, how do the English values compare with those produced in other 
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countries? Over a dozen EQ-5D-5L value set studies are underway internationally, using 
the same protocol used in this study, and future research can compare these in detail. 
Finally, although there is evidence to support the face validity of the data used to 
produce this value set, there are many remaining methodological issues that, if 
addressed, may help to further improve data quality. For example, changes to the way in 
which the stated preference tasks and health states are presented to participants may 
yield improved data. There are also a range of other promising preference elicitation 
methods that may be used to generate values, such as DCE designs that include an 
attribute for duration, and can therefore be modelled directly onto the 0 to 1 QALY scale 
(Mulhern et al., 2014; Bansback, et al., 2012). Error! Reference source not 
found.While new methods in this research area will continue to be developed, the value 
set reported here provides a robust and up-to-date basis for summarising EQ-5D-5L data 
in decision making. 
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